Fundamental Analysis Of Sun Pharma – Financials & More Details

Fundamental Analysis of Sun Pharma: Sun Pharma is the largest pharma company in India and the 15th largest listed company in terms of market capitalization. Plus, its stock has generated a sweet return of more than 100% to its investors in the last five years, against NIFTY 50’s 74% return. Can the investors of this large cap stock expect similar returns in the future? Is it a good bet for new investors? We’ll attempt to answer these and other questions by performing a fundamental analysis of Sun Pharma. Fundamental Analysis of Sun Pharma We’ll being our study of the company by getting ourselves acquainted with its business, scale and diversity of its operations. Next, we’ll learn about the pharma industry landscape. After that, we’ll go through the financials of the pharma stock. A highlight of the future plans and a summary conclude the article at the end. Company Overview Sun Pharmaceutical Industries Ltd. was founded by Dilip Shanghvi in 1983. Over the last 40 years, it has become the largest pharma company in India and the fourth-largest speciality generic pharmaceutical company in the world with a market capitalisation of Rs 2,25,000 crore. The pharma giant employs over 38,000 people globally. It has 43 production sites spread across various countries to formulate and manufacture injectables, sprays, ointments, creams, liquids, tablets and capsules. Overall, the company has operations in more than 100 countries across the globe. The drug maker has grown organically and inorganically over the years acquiring some well-known names such as Ranbaxy and Concert Pharmaceuticals. It presently houses some of the world’s well-known brands such as Volini, Revital, Xelpros, and Abzorb. Sun Pharma segregates its business into four key divisions: India Branded Formulations, US Formulations, Emerging Markets, and the Rest of the World. These divisions have been arranged geographically and the company has a different product portfolio across these divisions. We’ll read more about this in the next section of our fundamental analysis of Sun Pharma. Segment Analysis The company has leadership in different product categories in different markets: Sun Pharma’s fast-growing India Branded Formulations segment positions it as the largest pharma company in India with a market share of 8.5% making it a leader in the chronic segment. Neuro-Psychiatry, Gastroenterology, Anti-Infectives, Diabetology, and Analgesics are its largest revenue contributors. The US Formulations segment has a key presence in a speciality, generics & OTC sub-segments in Dermatology, Ophthalmology and Onco Dermatology. Romania, Russia, South Africa, Brazil, Mexico and other 75 countries make up the Emerging Markets division where the company markets a vast basket of branded generics. The Rest of the World includes Western Europe, Canada, Japan, ANZ, Israel & other markets. Here the pharma giant develops, sources and markets complex generics and differentiated speciality, hospital & retail products. The table below showcases the revenue share of different divisions of Sun Pharma over the last four fiscal years. Revenue Segment FY19 FY20 FY21 FY22 India Branded Formulations 27.2 31.5 33.0 35.0 US Formulations 38.1 33.8 31.2 30.5 Emerging Markets 20.5 19.2 19.3 18.9 Rest of World 14.2 15.5 16.6 15.5 (figures in %) We can clearly see that the share of Sun Pharma’s domestic revenue in total revenue has grown over the years while that of US formulations has come down. Now we have a good understanding of the company and its various divisions. Let us move forward to read about the pharma industry landscape in the next section of our fundamental analysis of Sun Pharmaceutical Industries. Industry Overview The global pharmaceutical is projected to grow at a CAGR of 3-6% to reach $1.8 trillion in value by 2026. Excluding the Covid-19 vaccine demand, the sector is projected to expand at a 5% (approx.) annualised rate. As for regional demand, the developed markets (the US, United Kingdom, France, Italy, Germany, Spain and others) are expected to grow at a slower pace of 2-5% than pharmemerging nations (India, China, Brazil, Russia, and others) growth rate of 5-8%. Furthermore, India’s (the largest revenue segment of Sun Pharma) pharmaceuticals industry, the 3rd largest globally in terms of volume and 11th largest in terms of value is anticipated to grow at a much faster rate of 8-11% every year during this period. During the period, the growth will be partly offset by rising competition from generics & biosimilars and the loss of exclusivity. Going forward, a variety of factors including higher volumes, new treatments in Oncology & Immunology, adoption of speciality medicines, the negative impact of evolving lifestyles and food habits, improvements in healthcare access, increasing disposable income, and growing insurance coverage will be key growth drivers of the pharma industry. We have covered the hard parts by understanding the business and the pharmaceutical industry landscape across the world. Now we’ll race through financials of the the stock. Sun Pharma – Financials Revenue & Net Profit Growth The revenues of Sun Pharmaceuticals grew at a CAGR of 7.39% from Rs 29,066 crore in FY19 to Rs 38,654 crore in FY22. During the same period, the profit growth was weak at 1.37% only, affected by anti-trust settlements, impairment of intangible assets, restructuring of operations, and more. The table below presents the operating revenue and net profit of Sun Pharmaceuticals Industries. Fiscal Year Operating Revenue Net Profit 2023 TBA TBA 2022 38,654 3,389 2021 33,498 2,272 2020 32,838 4,187 2019 29,066 3,209 4-Yr CAGR 7.39% 1.37% (figures in Rs Cr except for CAGR)Profit Margins Moving on to studying the margins, the EBITDA margins (earnings before interest, tax, depreciation and amortization) and net profit margins (adjusted for exceptional items) have expanded during our study period aided by better realisations and higher volumes. The table below showcases the improving EBITDA margin and adjusted net profit margins of Sun Pharma over the last few financial years. Fiscal Year EBITDA Margin Adj. Net Profit Margin 2023 TBA TBA 2022 26.9 20.0 2021 25.3 17.8 2020 21.3 12.5 2019 21.7 13.5 (figures in %) Better margins coupled with volume growth translate into higher profitability. Let us analyse the profitability of our pharma stock in the next section of our fundamental analysis of Sun Pharmaceuticals Industries. Return Ratios: RoE & RoE Excluding the effect of exceptional items, the profitability metrics or return ratios: return on capital employed (RoCE) and return on equity (RoE) have remained strong over the years. This has partially aided the stock to uphold the interest of investors in the stock. The figures below represent the adjusted RoCE and RoE of Sun Pharmaceuticals Industries for the last few fiscals. Fiscal Year RoCE RoE 2023 TBA TBA 2022 16.4 15.0 2021 13.5 12.5 2020 11.0 9.1 2019 11.8 9.4 (figures in %)Debt Analysis We’ll keep our debt analysis short as the pharma giant is a debt-free company. Sun Pharmaceuticals Industries has a nil debt-to-equity ratio of 0.03 with a high-interest coverage ratio of 89 times. Future Plans Of Sun Pharma So far we looked at the previous fiscals’ data for our fundamental analysis of Sun Pharma. In this section, let us try to understand what lies ahead for the company and its investors. The company deployed Rs 2,219 crore, 5.8% of the fiscal revenue towards research and development in FY22 the benefits of which shall accrue in the coming years. The management is bullish on its 4 molecules under development in the speciality R&D pipeline as the segment is anticipated to be a key growth driver in the developed markets. Sun Pharma in-licensed and commercialised an anti-acne product in the US market. It is receiving a good response and is anticipated to bring higher sales in the coming years. Furthermore, it is targeting volume growth in emerging markets and the rest of the world to improve the profitability of newly entered markets. In addition to all this, its recent launches and acquisitions such as Sezaby, Concert Pharmaceuticals, Uractiv, and Alchemee will bring revenue growth in coming years. Fundamental Analysis of Sun Pharma- Key Metrics We are almost at the end of our fundamental analysis of Sun Pharmaceutical Industries. Let us take a quick look at the key metrics of the stock. CMP ₹938 Market Cap (Cr.) ₹225,000 EPS ₹17.6 P/E Ratio 28 Book Value ₹221 P/B Ratio 4.3 EBITDA Margin 26.9% Net Profit Margin 20.0% Debt to Equity 0.0 Interest Coverage 89 Promoter Holding 54.5% RoE 15% Conclusion The investors in Sun Pharmaceutical Industries have maintained their faith in the stock despite the recent setbacks. The bottom line growth will be a key factor that the present and prospective investors should track closely. As the company has left its various worries behind, do you think the investors can expect higher returns in the future? Or the possible future earnings are already discounted in the present stock price as it trades at a TTM P/E ratio of 17.55 which is below the sector P/E of 21.27? How about we continue this conversation in the comments below? By utilizing the stock screener, stock heatmap, portfolio backtesting, and stock compare tool on the Trade Brains portal, investors gain access to comprehensive tools that enable them to identify the best stocks also get updated with stock market news, and make well-informed investment decisions. The post Fundamental Analysis Of Sun Pharma – Financials & More Details appeared first on Trade Brains. [Image] Here are Some More Investing Tips and Resources. Enjoy! Sponsored [Unlock a 15x ROI with Alternative Energy Investment]( Are you searching for a lucrative investment opportunity in today's unpredictable market? We have the perfect solution for you: the alternative energy sector, promising an incredible 15x return on investment.[Go HERE to see the Potential Investing Opportunity]( By clicking the link you are subscribing to The Premium Market News Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. [Privacy Policy/Disclosures]( [Fundamental Analysis Of Sun Pharma – Financials & More Details](?site= Fundamental Analysis of Sun Pharma: Sun Pharma is the largest pharma company in India and the 15th largest listed company in terms of market capitalization. Plus, its stock has generated a sweet return of more than 100% to its investors in the last five years, against NIFTY 50’s 74% return. Can the investors of this large cap stock expect similar returns in the future? Is it a good bet for new investors? We’ll attempt to answer these and other questions by performing a fundamental analysis of Sun Pharma. Fundamental Analysis of Sun Pharma We’ll being our study of the company by getting ourselves acquainted with its business, scale and diversity of its operations. Next, we’ll learn about the pharma industry landscape. After that, we’ll go through the financials of the pharma stock. A highlight of the future plans and a summary conclude the article at the end. Company Overview Sun Pharmaceutical Industries Ltd. was founded by Dilip Shanghvi in 1983. Over the last 40 years, it has become the largest pharma company in India and the fourth-largest speciality generic pharmaceutical company in the world with a market capitalisation of Rs 2,25,000 crore. The pharma giant employs over 38,000 people globally. It has 43 production sites spread across various countries to formulate and manufacture injectables, sprays, ointments, creams, liquids, tablets and capsules. Overall, the company has operations in more than 100 countries across the globe. The drug maker has grown organically and inorganically over the years acquiring some well-known names such as Ranbaxy and Concert Pharmaceuticals. It presently houses some of the world’s well-known brands such as Volini, Revital, Xelpros, and Abzorb. Sun Pharma segregates its business into four key divisions: India Branded Formulations, US Formulations, Emerging Markets, and the Rest of the World. These divisions have been arranged geographically and the company has a different product portfolio across these divisions. We’ll read more about this in the next section of our fundamental analysis of Sun Pharma. Segment Analysis The company has leadership in different product categories in different markets: Sun Pharma’s fast-growing India Branded Formulations segment positions it as the largest pharma company in India with a market share of 8.5% making it a leader in the chronic segment. Neuro-Psychiatry, Gastroenterology, Anti-Infectives, Diabetology, and Analgesics are its largest revenue contributors. The US Formulations segment has a key presence in a speciality, generics & OTC sub-segments in Dermatology, Ophthalmology and Onco Dermatology. Romania, Russia, South Africa, Brazil, Mexico and other 75 countries make up the Emerging Markets division where the company markets a vast basket of branded generics. The Rest of the World includes Western Europe, Canada, Japan, ANZ, Israel & other markets. Here the pharma giant develops, sources and markets complex generics and differentiated speciality, hospital & retail products. The table below showcases the revenue share of different divisions of Sun Pharma over the last four fiscal years. Revenue Segment FY19 FY20 FY21 FY22 India Branded Formulations 27.2 31.5 33.0 35.0 US Formulations 38.1 33.8 31.2 30.5 Emerging Markets 20.5 19.2 19.3 18.9 Rest of World 14.2 15.5 16.6 15.5 (figures in %) We can clearly see that the share of Sun Pharma’s domestic revenue in total revenue has grown over the years while that of US formulations has come down. Now we have a good understanding of the company and its various divisions. Let us move forward to read about the pharma industry landscape in the next section of our fundamental analysis of Sun Pharmaceutical Industries. Industry Overview The global pharmaceutical is projected to grow at a CAGR of 3-6% to reach $1.8 trillion in value by 2026. Excluding the Covid-19 vaccine demand, the sector is projected to expand at a 5% (approx.) annualised rate. As for regional demand, the developed markets (the US, United Kingdom, France, Italy, Germany, Spain and others) are expected to grow at a slower pace of 2-5% than pharmemerging nations (India, China, Brazil, Russia, and others) growth rate of 5-8%. Furthermore, India’s (the largest revenue segment of Sun Pharma) pharmaceuticals industry, the 3rd largest globally in terms of volume and 11th largest in terms of value is anticipated to grow at a much faster rate of 8-11% every year during this period. During the period, the growth will be partly offset by rising competition from generics & biosimilars and the loss of exclusivity. Going forward, a variety of factors including higher volumes, new treatments in Oncology & Immunology, adoption of speciality medicines, the negative impact of evolving lifestyles and food habits, improvements in healthcare access, increasing disposable income, and growing insurance coverage will be key growth drivers of the pharma industry. We have covered the hard parts by understanding the business and the pharmaceutical industry landscape across the world. Now we’ll race through financials of the the stock. Sun Pharma – Financials Revenue & Net Profit Growth The revenues of Sun Pharmaceuticals grew at a CAGR of 7.39% from Rs 29,066 crore in FY19 to Rs 38,654 crore in FY22. During the same period, the profit growth was weak at 1.37% only, affected by anti-trust settlements, impairment of intangible assets, restructuring of operations, and more. The table below presents the operating revenue and net profit of Sun Pharmaceuticals Industries. Fiscal Year Operating Revenue Net Profit 2023 TBA TBA 2022 38,654 3,389 2021 33,498 2,272 2020 32,838 4,187 2019 29,066 3,209 4-Yr CAGR 7.39% 1.37% (figures in Rs Cr except for CAGR)Profit Margins Moving on to studying the margins, the EBITDA margins (earnings before interest, tax, depreciation and amortization) and net profit margins (adjusted for exceptional items) have expanded during our study period aided by better realisations and higher volumes. The table below showcases the improving EBITDA margin and adjusted net profit margins of Sun Pharma over the last few financial years. Fiscal Year EBITDA Margin Adj. Net Profit Margin 2023 TBA TBA 2022 26.9 20.0 2021 25.3 17.8 2020 21.3 12.5 2019 21.7 13.5 (figures in %) Better margins coupled with volume growth translate into higher profitability. Let us analyse the profitability of our pharma stock in the next section of our fundamental analysis of Sun Pharmaceuticals Industries. Return Ratios: RoE & RoE Excluding the effect of exceptional items, the profitability metrics or return ratios: return on capital employed (RoCE) and return on equity (RoE) have remained strong over the years. This has partially aided the stock to uphold the interest of investors in the stock. The figures below represent the adjusted RoCE and RoE of Sun Pharmaceuticals Industries for the last few fiscals. Fiscal Year RoCE RoE 2023 TBA TBA 2022 16.4 15.0 2021 13.5 12.5 2020 11.0 9.1 2019 11.8 9.4 (figures in %)Debt Analysis We’ll keep our debt analysis short as the pharma giant is a debt-free company. Sun Pharmaceuticals Industries has a nil debt-to-equity ratio of 0.03 with a high-interest coverage ratio of 89 times. Future Plans Of Sun Pharma So far we looked at the previous fiscals’ data for our fundamental analysis of Sun Pharma. In this section, let us try to understand what lies ahead for the company and its investors. The company deployed Rs 2,219 crore, 5.8% of the fiscal revenue towards research and development in FY22 the benefits of which shall accrue in the coming years. The management is bullish on its 4 molecules under development in the speciality R&D pipeline as the segment is anticipated to be a key growth driver in the developed markets. Sun Pharma in-licensed and commercialised an anti-acne product in the US market. It is receiving a good response and is anticipated to bring higher sales in the coming years. Furthermore, it is targeting volume growth in emerging markets and the rest of the world to improve the profitability of newly entered markets. In addition to all this, its recent launches and acquisitions such as Sezaby, Concert Pharmaceuticals, Uractiv, and Alchemee will bring revenue growth in coming years. Fundamental Analysis of Sun Pharma- Key Metrics We are almost at the end of our fundamental analysis of Sun Pharmaceutical Industries. Let us take a quick look at the key metrics of the stock. CMP ₹938 Market Cap (Cr.) ₹225,000 EPS ₹17.6 P/E Ratio 28 Book Value ₹221 P/B Ratio 4.3 EBITDA Margin 26.9% Net Profit Margin 20.0% Debt to Equity 0.0 Interest Coverage 89 Promoter Holding 54.5% RoE 15% Conclusion The investors in Sun Pharmaceutical Industries have maintained their faith in the stock despite the recent setbacks. The bottom line growth will be a key factor that the present and prospective investors should track closely. As the company has left its various worries behind, do you think the investors can expect higher returns in the future? Or the possible future earnings are already discounted in the present stock price as it trades at a TTM P/E ratio of 17.55 which is below the sector P/E of 21.27? How about we continue this conversation in the comments below? By utilizing the stock screener, stock heatmap, portfolio backtesting, and stock compare tool on the Trade Brains portal, investors gain access to comprehensive tools that enable them to identify the best stocks also get updated with stock market news, and make well-informed investment decisions. The post Fundamental Analysis Of Sun Pharma – Financials & More Details appeared first on Trade Brains. [Continue Reading...](?site= [Fundamental Analysis Of Sun Pharma – Financials & More Details]( And, in case you missed it: - [Morning Report: Strong jobs report](?site= - [How to Adjust a Poor Man’s Covered Call (PMCC) Trade to Align with the BCI Trade Initialization Formula](?site= - [Australian Mining Stocks as Long Term Investments](?site= - [Top Clicks on Alpha Ideas this Week](?site= - [BETA TEST from DGS](?site= - FREE OR LOW COST INVESTING RESOURCES - [i]( [i]( [i]( [i]( Sponsored [This Could Become Your Favorite Stock In A Recession]( Financial experts are split on the recession. Some deny, some say it’s already started, and some are giving new silly names like a “rolling recession” to try to make sense of it. The fact is much of the market believes a big recession is still coming...[Get the FULL Report Here]( By clicking link you are subscribing to The Investor Newsletter Daily Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. [Privacy Policy/Disclosures]( - CLICK THE IMAGE BELOW FOR MORE INFORMATION - [i]( Good Investing! T. D. Thompson Founder & CEO [ProfitableInvestingTips.com]() ProfitableInvestingTips.com is an informational website for men and women who want to discover investing and trading products and strategies to educate themselves about the risks and benefits of investing and investing-related products. DISCLAIMER: Use of this Publisher's email, website and content, is subject to the Privacy Policy and Terms of Use published on Publisher's Website. Content marked as "sponsored" may be third party advertisements and are not endorsed or warranted by our staff or company. The content in our emails is for informational or entertainment use, and is not a substitute for professional advice. Always check with a qualified professional regarding investing and trading guidance. Be sure to do your own careful research before taking action based on anything you find in this content. If you no longer wish to receive our emails, click the link below: [Unsubscribe]( Net Wealth Consultants 6614 La Mora Drive Houston, Texas 77083 United States (888) 983-9123